Download Free Sample Report

The global Cell and Gene Therapy Drug Delivery Devices market was valued at US$ 221.49 million in 2023 and is projected to reach US$ 368.29 million by 2030, at a CAGR of 7.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Cell and gene therapy drug delivery industry is a transformative industry whose full potential is only just beginning to emerge. Cell and gene therapy involves the extraction of cells, protein, or genetic material (DNA) from the donor, and altering them to provide highly personalized therapy. Cell and gene therapies may offer longer-lasting effects than traditional medicines. One of the significant drugs of the cell and gene therapy industry is CAR-T cell-based medicines, which include both cell therapy and gene therapy. Various market players are actively investing in the research and development of the cell and gene therapy industry. The players are offering improved and new products, which meet the critical needs of patients.
This report aims to provide a comprehensive presentation of the global market for Cell and Gene Therapy Drug Delivery Devices, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell and Gene Therapy Drug Delivery Devices. This report contains market size and forecasts of Cell and Gene Therapy Drug Delivery Devices in global, including the following market information:

• Global Cell and Gene Therapy Drug Delivery Devices Market Revenue, 2019-2024, 2025-2030, ($ millions)
• Global top five companies in 2023 (%)

Sterile Insulin Syringe Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Cell and Gene Therapy Drug Delivery Devices include Amgen, Inc., Bausch and Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cell Institute and Kite Pharma, Inc., etc. in 2023, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cell and Gene Therapy Drug Delivery Devices companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cell and Gene Therapy Drug Delivery Devices Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Cell and Gene Therapy Drug Delivery Devices Market Segment Percentages, by Type, 2023 (%)

• Sterile Insulin Syringe
• Pre-Filled Syringe
• Infusion Bags

Global Cell and Gene Therapy Drug Delivery Devices Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Cell and Gene Therapy Drug Delivery Devices Market Segment Percentages, by Application, 2023 (%)

• Luxturna
• Kymriah
• Provenge
• Zolgensma
• Yescarta
• Strimvelis

Global Cell and Gene Therapy Drug Delivery Devices Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Cell and Gene Therapy Drug Delivery Devices Market Segment Percentages, By Region and Country, 2023 (%)

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cell and Gene Therapy Drug Delivery Devices revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Cell and Gene Therapy Drug Delivery Devices revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:

• Amgen, Inc.
• Bausch and Lomb Incorporated
• Becton, Dickinson and Company
• Bluebird bio, Inc.
• Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
• Dendreon Pharmaceuticals LLC.
• Helixmith Co., Ltd (ViroMed Co., Ltd)
• Human Stem Cell Institute
• Kite Pharma, Inc.
• Kolon Tissue Gene, inc.
• Novartis AG
• Orchard Therapeutics plc.
• Pfizer, Inc.
• Renova Therapeutics
• Spark Therapeutics, Inc.
• uniQure N.V.
• Vericel Corporation

Outline of Major Chapters:

• Chapter 1: Introduces the definition of Cell and Gene Therapy Drug Delivery Devices, market overview.
• Chapter 2: Global Cell and Gene Therapy Drug Delivery Devices market size in revenue.
• Chapter 3: Detailed analysis of Cell and Gene Therapy Drug Delivery Devices company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
• Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
• Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
• Chapter 6: Sales of Cell and Gene Therapy Drug Delivery Devices in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
• Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
• Chapter 8: The main points and conclusions of the report.